Jean-Louis Georges
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jean-Louis Georges has a total of 401 co-authors. Here are the top co-authors by number of shared publications:
B. Livarek
Service de cardiologie, centre hospitalier de Versailles, hôpital André Mignot, 177 rue de Versailles, 78150 Le Chesnay, France
18 shared publicationsG. Gibault-Genty
Service de cardiologie, centre hospitalier de Versailles, 78150 Le-Chesnay, France
9 shared publicationsBernard Livarek
Affiliation Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay, France
8 shared publicationsE. Blicq
Service de cardiologie, centre hospitalier de Versailles, hôpital André Mignot, 177 rue de Versailles, 78150 Le Chesnay, France
8 shared publicationsN. Baron
7 shared publicationsR. Convers-Domart
Service de cardiologie, centre hospitalier de Versailles, 78150 Le-Chesnay, France
7 shared publications
Latest Publications
- 2 July 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (11) , 605-612
Diagnostic value of cardiac magnetic resonance imaging for myocardial infarction with non-obstructive coronary arteries: The CRIMINAL prospective registry
- 2 July 2025
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 118 (11) , 605-612
Diagnostic value of cardiac magnetic resonance imaging for myocardial infarction with non-obstructive coronary arteries: The CRIMINAL prospective registry
- 22 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (29) , 2894-2902
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial
Background and Aims: This study aims to report the effects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuation of β-blocker treatment after a myocardial infarction (MI). Methods: Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients of the AβYSS trial with a median follow-up of 3.0 years. Additionally, changes in HR and BP and the impact on the primary endpoint (death, MI, stroke, hospitalization for cardiovascular reason) in the pre-specified subgroups of patients with or without history of hypertension were assessed using linear mixed repeated and adjusted Cox proportional hazards model, respectively. Results: β-blocker interruption was associated with significant increase {least square mean difference [95% confidence interval (CI)]} in systolic BP [+3.7 (2.6, 4.8) mmHg, P < .001], diastolic BP [+3.3 (2.6, 4.0) mmHg, P < .001], and resting HR [+10 [9, 11) b.p.m., P < .001] at 6 months that persisted over the duration of follow-up despite an increase in antihypertensive drugs in the β-blocker interruption group. The effects were observed in both hypertensive (43% of the population) and non-hypertensive patients. Hypertensive patients were at higher risk of events (25.8% vs. 19.2%) as compared with patients without hypertension (adjusted hazard ratio 1.18, 95% CI 1.01–1.36, P = .03). Patients with hypertension had a particularly marked increase in the primary endpoint (risk difference 5.02%, 0.72%–9.32%, P = .014) when randomized to β-blocker interruption. Conclusions: Interruption of β-blocker treatment after an uncomplicated MI led to a sustained increase in BP and HR, with potentially deleterious effects on outcomes, especially in patients with history of hypertension.
- 22 May 2025
- Published by Oxford University Press (OUP) in European Heart Journal
- Vol. 46 (29) , 2894-2902
Beta-blocker interruption effects on blood pressure and heart rate after myocardial infarction: the AβYSS trial
Background and Aims: This study aims to report the effects of β-blocker interruption on blood pressure (BP) and heart rate (HR) in the AβYSS trial where patients were randomized to interruption or continuation of β-blocker treatment after a myocardial infarction (MI). Methods: Changes in HR and BP from baseline to post-randomization are reported using linear mixed repeated model, in the 3698 patients of the AβYSS trial with a median follow-up of 3.0 years. Additionally, changes in HR and BP and the impact on the primary endpoint (death, MI, stroke, hospitalization for cardiovascular reason) in the pre-specified subgroups of patients with or without history of hypertension were assessed using linear mixed repeated and adjusted Cox proportional hazards model, respectively. Results: β-blocker interruption was associated with significant increase {least square mean difference [95% confidence interval (CI)]} in systolic BP [+3.7 (2.6, 4.8) mmHg, P < .001], diastolic BP [+3.3 (2.6, 4.0) mmHg, P < .001], and resting HR [+10 [9, 11) b.p.m., P < .001] at 6 months that persisted over the duration of follow-up despite an increase in antihypertensive drugs in the β-blocker interruption group. The effects were observed in both hypertensive (43% of the population) and non-hypertensive patients. Hypertensive patients were at higher risk of events (25.8% vs. 19.2%) as compared with patients without hypertension (adjusted hazard ratio 1.18, 95% CI 1.01–1.36, P = .03). Patients with hypertension had a particularly marked increase in the primary endpoint (risk difference 5.02%, 0.72%–9.32%, P = .014) when randomized to β-blocker interruption. Conclusions: Interruption of β-blocker treatment after an uncomplicated MI led to a sustained increase in BP and HR, with potentially deleterious effects on outcomes, especially in patients with history of hypertension.
- 23 September 2024
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 73 (5) , 101802
Évaluation préliminaire de l'intérêt d'une cellule d'optimisation thérapeutique sur la titration des traitements de l'insuffisance cardiaque à fraction d’éjection ventriculaire gauche réduite et la qualité de vie des patients
- 23 September 2024
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 73 (5) , 101802
Évaluation préliminaire de l'intérêt d'une cellule d'optimisation thérapeutique sur la titration des traitements de l'insuffisance cardiaque à fraction d’éjection ventriculaire gauche réduite et la qualité de vie des patients
- 21 September 2024
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 73 (5) , 101808
Myocardite aiguë secondaire à une maladie de Basedow : à propos d'un cas
- 21 September 2024
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 73 (5) , 101808
Myocardite aiguë secondaire à une maladie de Basedow : à propos d'un cas
- 4 July 2024
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (10) , 561-568
Intensive therapeutic education strategy for patients with acute heart failure (EduStra-HF): Design of a randomized controlled trial
- 4 July 2024
- Published by Elsevier in Archives of Cardiovascular Diseases
- Vol. 117 (10) , 561-568
Intensive therapeutic education strategy for patients with acute heart failure (EduStra-HF): Design of a randomized controlled trial
- 20 October 2023
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 72 (5) , 101693
Miscellanées en soins intensifs cardiologiques
- 20 October 2023
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 72 (5) , 101693
Miscellanées en soins intensifs cardiologiques
- 17 October 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (10) , e257010
Acute myocardial damage after electrical injury assessed by MRI
Electrical injuries are not uncommon, and electrical shock-induced cardiac damage can be life-threatening. We present the case of a young patient who suffered from acute myocardial damage due to an occupational electric shock. Myocardial damage was assessed by very early (day 4) and repeated (up to month 18) MRI. Clinical management and patient risk estimation in such a setting are challenging because data on similar non-lethal cases and practice recommendations are scarce in the literature.
- 17 October 2023
- Published by BMJ in BMJ Case Reports
- Vol. 16 (10) , e257010
Acute myocardial damage after electrical injury assessed by MRI
Electrical injuries are not uncommon, and electrical shock-induced cardiac damage can be life-threatening. We present the case of a young patient who suffered from acute myocardial damage due to an occupational electric shock. Myocardial damage was assessed by very early (day 4) and repeated (up to month 18) MRI. Clinical management and patient risk estimation in such a setting are challenging because data on similar non-lethal cases and practice recommendations are scarce in the literature.
- 6 September 2023
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 72 (5) , 101644
Tachycardie ventriculaire récidivante révélant une sarcoïdose cardiaque
- 6 September 2023
- Published by Elsevier in Annales de Cardiologie et d'Angéiologie
- Vol. 72 (5) , 101644
Tachycardie ventriculaire récidivante révélant une sarcoïdose cardiaque
- 2 June 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (15) , 1945-1954
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Aims: In Europe, global data on guideline adherence, geographic variations, and determinants of clinical events in patients with chronic coronary syndrome (CCS) remain suboptimal. The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Chronic Ischemic Cardiovascular Disease Long-Term (CICD-LT) registry is a prospective European registry, and was designed to describe the profile, management, and outcomes of patients with CCS across the ESC countries. Methods and results: We aimed to investigate clinical events at 1-year follow-up from the ESC EORP CICD-LT registry. One-year outcomes of 6655 patients from the 9174 recruited in this European registry were analysed. Overall, 168 patients (2.5%) died, mostly from cardiovascular (CV) causes (n = 97, 1.5%). Northern Europe had the lowest CV mortality rate, while southern Europe had the highest (0.5 vs. 2.0%, P = 0.04). Women had a higher rate of CV mortality compared with men (2.0 vs. 1.3%, P = 0.02). During follow-up, 1606 patients (27.1%) were hospitalized at least once, predominantly for CV indications (n = 1220, 20.6%). Among the population with measured low-density lipoprotein-cholesterol level at 1 year, 1434 patients (66.5%) were above the recommended target. Age, history of atrial fibrillation, previous stroke, liver disease, chronic obstructive pulmonary disease or asthma, increased serum creatinine, and impaired left ventricular function were associated with an increased risk of CV death or hospitalization. Conclusion: In the CICD registry, the majority of patients with CCS have uncontrolled CV-risk factors. The 1-year mortality rate is low, but these patients are frequently hospitalized for CV causes. Early identification of comorbidities may represent an opportunity for enhanced care and better outcomes.
- 2 June 2022
- Published by Oxford University Press (OUP) in European Journal of Preventive Cardiology
- Vol. 29 (15) , 1945-1954
Impact of chronic coronary syndromes on cardiovascular hospitalization and mortality: the ESC-EORP CICD-LT registry
Aims: In Europe, global data on guideline adherence, geographic variations, and determinants of clinical events in patients with chronic coronary syndrome (CCS) remain suboptimal. The European Society of Cardiology (ESC) EURObservational Research Programme (EORP) Chronic Ischemic Cardiovascular Disease Long-Term (CICD-LT) registry is a prospective European registry, and was designed to describe the profile, management, and outcomes of patients with CCS across the ESC countries. Methods and results: We aimed to investigate clinical events at 1-year follow-up from the ESC EORP CICD-LT registry. One-year outcomes of 6655 patients from the 9174 recruited in this European registry were analysed. Overall, 168 patients (2.5%) died, mostly from cardiovascular (CV) causes (n = 97, 1.5%). Northern Europe had the lowest CV mortality rate, while southern Europe had the highest (0.5 vs. 2.0%, P = 0.04). Women had a higher rate of CV mortality compared with men (2.0 vs. 1.3%, P = 0.02). During follow-up, 1606 patients (27.1%) were hospitalized at least once, predominantly for CV indications (n = 1220, 20.6%). Among the population with measured low-density lipoprotein-cholesterol level at 1 year, 1434 patients (66.5%) were above the recommended target. Age, history of atrial fibrillation, previous stroke, liver disease, chronic obstructive pulmonary disease or asthma, increased serum creatinine, and impaired left ventricular function were associated with an increased risk of CV death or hospitalization. Conclusion: In the CICD registry, the majority of patients with CCS have uncontrolled CV-risk factors. The 1-year mortality rate is low, but these patients are frequently hospitalized for CV causes. Early identification of comorbidities may represent an opportunity for enhanced care and better outcomes.